SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: luckydog887/24/2025 10:33:58 AM
1 Recommendation

Recommended By
jhcimmu

   of 63276
 
SRPT:

talk about a divergence of analyst opinions this morning ........

Citigroup analyst Yigal Nochomovitz initiates coverage on Sarepta Therapeutics(SRPT) with a Sell rating and announces Price Target of $7.

Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics(SRPT) with a Overweight and lowers the price target from $65 to $48.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News